MARKET

VTGN

VTGN

Vistagen Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.020
0.000
0.00%
After Hours: 1.020 0 0.00% 17:28 05/26 EDT
OPEN
1.010
PREV CLOSE
1.020
HIGH
1.035
LOW
1.000
VOLUME
606.11K
TURNOVER
0
52 WEEK HIGH
3.550
52 WEEK LOW
0.9618
MARKET CAP
210.66M
P/E (TTM)
-2.7717
1D
5D
1M
3M
1Y
5Y
VistaGen to Participate in Upcoming June Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 27, 2022--VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, de...
Business Wire · 13h ago
Stocks That Hit 52-Week Lows On Monday
  On Monday, 149 companies reached new 52-week lows.
Benzinga · 4d ago
What You Need To Know About VistaGen Therapeutics, Inc.'s (NASDAQ:VTGN) Investor Composition
A look at the shareholders of VistaGen Therapeutics, Inc. ( NASDAQ:VTGN ) can tell us which group is most powerful...
Simply Wall St. · 05/10 14:34
VistaGen says FDA found no signal of abuse potential for its nasal spray PH94B for anxiety
VistaGen Therapeutics (NASDAQ:VTGN) on Thursday said the U.S. Food and Drug Administration (FDA) agreed that the company's nasal spray PH94B for the acute treatment of social anxiety disorder (SAD) did
Seekingalpha · 05/05 14:56
VistaGen Therapeutics Highlights Regulatory Update For Its PH94B: 'FDA agreed that data from nonclinical and clinical studies of PH94B completed to date provide no signal of abuse potential'
The FDA agreed that data from nonclinical and clinical studies of PH94B completed to date provide no signal of abuse potential The FDA also agreed that additional nonclinical studies are not necessary to evaluate the
Benzinga · 05/05 12:42
BRIEF-VistaGen Announces Key Regulatory Update On Ph94B For The Acute Treatment Of Social Anxiety Disorder
reuters.com · 05/05 12:35
VistaGen Appoints Reid Adler as Chief Legal Officer
SOUTH SAN FRANCISCO, Calif., May 02, 2022--VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen) a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with a...
Business Wire · 05/02 12:00
VistaGen to Present Preclinical Data on Lead Candidate PH94B at Upcoming Scientific Congresses
SOUTH SAN FRANCISCO, Calif., April 21, 2022--VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen) a late clinical-stage, central nervous system (CNS) focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with...
Business Wire · 04/21 12:00
More
No Data
Learn about the latest financial forecast of VTGN. Analyze the recent business situations of Vistagen Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

75.00%Strong Buy
25.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average VTGN stock price target is 7.33 with a high estimate of 9.00 and a low estimate of 5.00.
High9.00
Average7.33
Low5.00
Current 1.060
EPS
Actual
Estimate
-0.16-0.12-0.08-0.04
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Institutional Holdings
Institutions: 124
Institutional Holdings: 134.70M
% Owned: 65.22%
Shares Outstanding: 206.53M
TypeInstitutionsShares
Increased
30
6.68M
New
17
1.73M
Decreased
37
11.08M
Sold Out
8
1.22M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Non-Executive Chairman/Independent Director
Jon Saxe
President/Founder/Chief Scientific Officer
H. Ralph Snodgrass
Chief Executive Officer/Director
Shawn Singh
Chief Financial Officer/Vice President/Secretary
Jerrold Dotson
Senior Vice President
Mark Ginski
Other/Director
Ann Cunningham
Other
Reid Adler
Other
Mark Smith
Independent Director
Joanne Curley
Independent Director
Margaret Fitzpatrick
Independent Director
Jerry Gin
Independent Director
Mary Rotunno
No Data
No Data
About VTGN
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). The company's pipeline includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that is preparing for Phase III clinical trial for social anxiety disorder (SAD), PH10, a neuroactive nasal spray that is planning for Phase 2b development as a stand-alone treatment for depressive disorder (MDD), and AV-101 which the Company is developing for the treatment of depressive disorder (MDD), suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID) and epilepsy. In addition, the Company has developed a human pluripotent stem cell (hPSC) technology platform, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs).

Webull offers kinds of Vistagen Therapeutics Inc stock information, including NASDAQ:VTGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VTGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VTGN stock methods without spending real money on the virtual paper trading platform.